Medlab Clinical (AU:MDC) has released an update.
Medlab Clinical reports a challenging first quarter of 2025, with no cash receipts and a closing cash balance of just $15,000. The company is in talks to acquire a business and aims to re-purpose its ASX listing, with plans to initiate re-compliance following the transaction. Financial expenditures for the quarter totaled $95,000, mainly for corporate expenses.
For further insights into AU:MDC stock, check out TipRanks’ Stock Analysis page.
